Trial Profile
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Sanofi Pasteur
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 04 Jan 2023 Planned End Date changed from 10 Jan 2023 to 11 Jan 2024.
- 04 Jan 2023 Planned primary completion date changed from 10 Jan 2023 to 11 Jan 2024.